A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
ApexOnco Front Page
Recent articles
So who else could be interested in the oestrogen degrader?
Meanwhile, investors await key clinical data.
But BeOne canned its alcestobart deal in May.
Tiragolumab failed the Skyscraper-14 and 03 studies, Roche quietly reveals.
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
There are questions about vuso-vec’s supporting and confirmatory trials.
